Tango Therapeutics Inc
$ 27.18
-1.41%
31 Jul - close price
- Market Cap 4,425,303,000 USD
- Current Price $ 27.18
- High / Low $ 27.95 / 26.32
- Stock P/E N/A
- Book Value 2.72
- EPS -0.83
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -0.38 %
- 52 Week High 34.39
- 52 Week Low 6.21
About
Tango Therapeutics Inc. is a leading clinical-stage biotechnology firm at the forefront of cancer treatment innovation, specializing in synthetic lethality and targeted therapies. With a robust pipeline of promising drug candidates focused on precision oncology, the company is uniquely positioned to address critical unmet needs in cancer care. Strategic collaborations with top academic institutions bolster its research and development efforts, enhancing its ability to deliver transformative therapeutic solutions. Tango Therapeutics aims to significantly improve patient outcomes and redefine treatment paradigms in oncology, making it a compelling investment opportunity in the biopharmaceutical landscape.
Analyst Target Price
$44.33
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-05 | 2025-11-04 | 2025-08-05 | 2025-05-12 | 2025-02-27 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-03-18 | 2023-11-08 | 2023-08-07 |
| Reported EPS | -0.32 | -0.29 | 0.13 | -0.35 | -0.36 | -0.34 | -0.27 | -0.24 | -0.35 | -0.32 | -0.23 | -0.23 |
| Estimated EPS | -0.2967 | -0.33 | -0.07 | -0.34 | -0.35 | -0.3428 | -0.37 | -0.35 | -0.31 | -0.28 | -0.34 | -0.34 |
| Surprise | -0.0233 | 0.04 | 0.2 | -0.01 | -0.01 | 0.0028 | 0.1 | 0.11 | -0.04 | -0.04 | 0.11 | 0.11 |
| Surprise Percentage | -7.8531% | 12.1212% | 285.7143% | -2.9412% | -2.8571% | 0.8168% | 27.027% | 31.4286% | -12.9032% | -14.2857% | 32.3529% | 32.3529% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.31 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TNGX
2026-07-28 17:09:59
This article from TradingKey provides an overview of Tango Therapeutics Inc (TNGX), including its current stock price and market capitalization. It attempts to present a revenue breakdown by business segment and region, but notes that this relevant data has not yet been disclosed by the company. The article focuses on the lack of publicly available detailed financial segment information for TNGX.
2026-07-28 04:41:58
Tango Therapeutics Inc (TNGX) has a robust financial status with a score of 8.24, ranking 57th in the Biotechnology & Medical Research industry, despite a 100% year-over-year decrease in quarterly revenue and a 14.14% decrease in net profit. The analysis highlights high operating efficiency and strong growth potential, although several key financial data points have not yet been disclosed by the company.
2026-07-26 06:10:40
Tango Therapeutics, Inc. (NASDAQ: TNGX) generated $62.38 million USD in revenue last year, primarily from its Oncology Therapies segment. This marks an increase from the previous year's $42.07 million USD. The majority of this revenue, $62.38 million USD, originated from the United States.
2026-07-26 05:10:19
This article provides a detailed quarterly and annual cash flow statement for Tango Therapeutics Inc (TNGX), covering operating, investing, and financing activities. It also includes frequently asked questions explaining different types of cash flow and TNGX's recent performance in these areas, such as its operating cash flow of -138.89M in fiscal 2025 and capital expenditures of 1.05M in the most recent quarter.
2026-07-25 11:43:15
This article details the shareholder structure of Tango Therapeutics Inc (TNGX), identifying its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activities by top firms. The report also lists related ETFs that include TNGX in their portfolios.
2026-07-24 23:40:33
This article provides a detailed quarterly and annual income statement for Tango Therapeutics Inc (TNGX). It includes key financial metrics such as total revenue, operating expenses, research and development expenses, operating profit, net non-operating interest income/expenses, other non-operating income/expenses, income before and after tax, net income, and earnings per share. The article also features an FAQ section explaining how to read an income statement, the difference between quarterly and annual statements, the meaning of YOY, and which metrics are most important for analyzing TNGX stock.
